Optinose Provides Corporate Updates; Expects To Produce Positive Income From Operations For Full Year 2025
Optinose Provides Corporate Updates; Expects To Produce Positive Income From Operations For Full Year 2025
Optinose提供公司最新情況；預計2025年全年運營收入將爲正數
In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31, 2024, representing growth of approximately 26% over the first quarter of 2023.
此外，該公司宣佈，截至2024年3月31日的三個月，XHANCE的初步產品淨收入爲1,490萬美元，比2023年第一季度增長約26％。
The Company expects peak XHANCE net revenues to exceed $300 million based on its current promotional focus on a specialty audience of mostly ENT and Allergy specialists.
該公司預計XHANCE的峯值淨收入將超過3億美元，這是基於其目前的促銷重點，主要是耳鼻喉科和過敏專家的專業受衆。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。